PHOENIX, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (CELZ), a clinical-stage biotechnology company focused on regenerative and immune cellular therapies, today ...
Investor's Business Daily on MSN
Incyte stock falls despite FDA breakthrough therapy fast track for rare blood cancer drug
The FDA granted Breakthrough Therapy status to Incyte's experimental treatment for a rare blood cancer. Incyte stock fell from near five-year highs.
The US FDA has approved mosunetuzumab-axgb (Lunsumio VELO) as a subcutaneous formulation for the treatment of adult patients ...
SAN DIEGO, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (CDTX), a biotechnology company using its proprietary Cloudbreak ® platform to develop drug-Fc conjugate (DFC) therapeutics, ...
The Breakthrough Therapy Designation was granted based on the positive topline results from the Essential3 Phase 3 program in essential ...
LEXINGTON, Mass., Oct. 23, 2025 /PRNewswire/ -- Partner Therapeutics, Inc. (PTx), a private, fully-integrated biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) ...
Findings from an interim analysis showed CELZ-201-DDT statistically significantly reduced pain and improved mobility in patients with chronic lower back pain. The Food and Drug Administration (FDA) ...
Please provide your email address to receive an email when new articles are posted on . Cidara announced Thursday that it received a breakthrough therapy designation from the FDA for an ...
Alphamab Oncology (stock code: 9966.HK) announced that the biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003, independently developed by the Company, and co-developed with JMT-Bio ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback